

Simpli-Fi Automation

AI-Powered Sensing Solutions for Life

Problem:

Preventing Hospital-Acquired Infections (HAI's)

Patient Safety- 1 in every 31 hospital patients is affected by HAIs at any given time, with tens of thousands of deaths annually.

Costly- HAIs cost the global economy billions of dollars annually, costing **\$25 billion** in the US alone, stemming from extended hospital stays, additional treatments, and readmissions.

Strain on resources- Extended hospital stays put a significant strain on hospital resources and staff.





Solution: Ai-powered sensing platform that uses NASA electronic nose technology to detect diseases in the air and breath.

**IMPROVE HEALTH
OUTCOMES**

When caring for patients in the hospital

CONTROL COST

Reduced infections = Reduced cost of care

BUILD TO SCALE

Real-time monitoring in every room

Market Size

Hospital-Acquired Infection Monitoring

Current-2023 (Global) **\$33.01 Billion**

Projected- 2028 (Global) **\$41.99 Billion**

CAGR 5.5%

*According to a MarketsandMarkets report published Feb 2024

TAM: \$33.01B

Global Hospital-Acquired
Infection Control and Prevention

SAM: \$13.04B

HAI infection monitoring

SOM: \$3.26B

Clinical IAQ

The Product:

AeroVeraTM Clinical Environmental Monitoring

The AeroVera IQ System provides continuous monitoring for airborne infectious Hazards:

- Measures wide-spectrum VOC's, Temperature, Humidity, pressure, and various fixed gases.
- Cost-effective C-Diff (Clostridium Difficile) monitoring in environmental room air.
- Uses "scent mapping" to detect airborne pathogens including; Staphylococcus, E. Coli, Streptococcus, Pseudomonas aeruginosa, and more.



AeroVera IQ



IQ Mini



Operating Room Air Quality Monitoring





Monitor Shared Spaces



Prevent Hospital Contracted Infection


Business Model: Hybrid SaaS

Subscription-based hardware and software



23,000,000
Hospital Beds

Market Share @ 2%



MONTHLY
SUBSCRIPTION
\$75 per device

Subscription fees




REVENUE
\$650M

2026-2030

C-Diff Detection: System Performance

Confusion Matrix



Highly Accurate C-Diff (Toxigenic) detection:

A total of 878 C-Diff samples were evaluated and distributed across three classes as follows:


- 292 samples belonging to the 'air' class
- 293 samples belonging to the 'cdiff-negative' class
- 293 samples belonging to the 'cdiff-positive' class

Correct predictions made by the model:

- 286 samples correctly predicted as 'air'
- 292 samples correctly predicted as 'cdiff-negative'
- 293 samples correctly predicted as 'cdiff-positive'

This results in a total of 871 correct predictions out of 878, yielding an overall accuracy of 99.2%.

Prediction Analysis: dataset/cdiff/cdiff-positive-toxic/C-Diff positive-51_Sensor 9_2025-06-15T22_42_58.538.xlsx



Our Partners




“We are enthusiastic about the possibilities this collaboration holds and look forward to working closely with Simpli-Fi Automation, Inc. to advance medical diagnostics and improve patient care.”

Dr. Alon Ben-Ari, CMIO Veterans Health Administration



“This technology has the potential to revolutionize remote health monitoring and provide a non-invasive tool for improving health outcomes for patients worldwide.”

Dr. Bruce D. Johnson, Department of Cardiovascular Medicine, Mayo Clinic



“The potential to mitigate the impact of hospital-transmitted diseases like C-Diff is particularly noteworthy, as it can significantly improve patient safety and quality of care.”

Dr. Sundar Manickam, Assistant Professor of Medicine, Cleveland Clinic Foundation



“We see immediate application uses in our mobile devices such as smartphones and wearables for fitness, wellness, and telehealth care. In addition, this sensor could be used in applications from food quality monitoring to environmental air quality monitoring through our network of partners and subsidiaries”

David Chon, Lead-MX Open Innovation, Samsung Research America



Milestones

Accomplished

- ✓ • Pre-Seed Round of \$1.8M
- ✓ • NASA Technology Partnership-
Research License Executed
- ✓ • NASA E-Nose
Commercialization License
Acquired
- ✓ • Provisional Patent filed
- ✓ • Proof of Concept-Alpha
Prototype Validation
- ✓ • \$1m in revenue (services)


Next 6 Months

- SEED round of \$10M
- Pre-Clinical Trials with The
Veterans Health Administration
- Phase 2-Clinical Trials with The
Veterans Health Administration
- AeroVera IQ Sales Rollout
- Manufacturing Scale-up
- 2,000 IQ units sold
- \$75k/Month in recurring revenue

Next 1-5 years

- Series A Round of \$35M
- AeroVera Breath
Development Completion
- Clinical Trials with The
Mayo Clinic (COPD)
- AeroVera Telehealth Sales
Roll-out
- 40,000-100,000 units sold
- \$2M-\$7M/Month in
recurring revenue

Global Revenue Forecast




* This pitch deck contains forward-looking financials that involve several risks and uncertainties. Actual results could materially differ from those anticipated.

The ask: We are seeking a total of \$10M during our seed round

Use of Funds:

- Continued R&D- 40%: We have completed the beta prototype design and are now moving into testing and validation.
- Clinical trials- 5%: We are self-funding our pre-clinical trials with the Veterans Administration and Mayo Clinic.
- Manufacturing Scale up: 20%: We are scaling up our manufacturing capabilities in St. Paul MN with \$1.2m in funding assistance from the Department of Employment and Economic Development (DEED).
- Operations- 15%: We are moving into the commercialization phase and need to fund operations.
- Marketing/Product Rollout- 20%: We are releasing our AeroVera IQ Product line in Q2 2026.



Join Simpli-Fi in Disrupting The Healthcare System by Investing Today!

Thank You!



chris@simplifiautomation.com



<https://simplifiautomation.com/>



1-863-289-8774



**370 Wabasha St. N. Suite 710
Saint Paul, MN 55102
United States**

 **Simpli-Fi**
Automation